Navigation Links
Milestone to Report Results for 2008 Third Quarter on Friday, November 14, 2008

Management to Host Teleconference on Monday, November 17, 2008 Beginning at 4:15 PM Eastern Time

LIVINGSTON, N.J., Nov. 11 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that the Company will report its third quarter 2008 financial results for the three and nine months ended September 30, 2008 on Friday, November 14, 2008.

Milestone Scientific will also host a teleconference on Monday, November 17, 2008, beginning at 4:15 PM Eastern Time, and invites all interested parties to join management in a discussion regarding the Company's financial results, corporate progression and other meaningful developments. The conference call can be accessed via telephone by dialing toll free 1-800-218-8862. For those unable to participate at that time, a replay of the teleconference can be accessed domestically by dialing 1-800-405-2236 and entering the passcode 11122141#. The replay will be available for 90 days.

About Milestone Scientific Inc.

Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(R) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The STA(TM) (Single Tooth Anesthesia) System, a computer-controlled local anesthesia delivery system, uses this technology to provide dentists with audible and visual signals as to in-tissue pressure. Milestone's existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's web site found at and

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of the Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report on Form 10-KSB for the year ended December 31, 2007. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.


Elite Financial Communications Group

Dodi Handy, President and CEO

For Media Inquiries: Tiffany Korkis or John Morrison, Directors, Elite

Media Group

407-585-1080 or via email at

SOURCE Milestone Scientific Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Heritage Labs Announces A1c Test Certification Milestone
3. Fifth DuraHeart(TM) U.S. Implant Marks Important Milestone in U.S. Pivotal Trial
4. Campus Celebrates Historic Milestone
5. Tishcon Corp Reaches Donation Milestone Exceeds 1 Million Bottles of Multi-Vitamins for Nourish America
6. eRT Completes Milestone 100th Thorough QT Study
7. Board of Directors of Milestone Scientific Names Joseph DAgostino Chief Financial Officer
8. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
9. Genmab Reaches Milestone in Ofatumumab Collaboration
10. DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels
11. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
Post Your Comments:
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... VANCOUVER , Nov. 24, 2015 /CNW/ - iCo ... ICOTF), today reported financial results for the quarter ... are expressed in Canadian dollars and presented under ... the United States ," said Andrew ... "These advancements regarding iCo-008 are not only value ...
(Date:11/24/2015)... Global, Inc., a worldwide provider of clinical research services headquartered in ... company has set a new quarterly earnings record in Q3 of ... for Q3 of 2014 to Q3 of 2015.   ... with the establishment of an Asia-Pacific office ... Kingdom and Mexico , with the ...
(Date:11/24/2015)... LEXINGTON, Massachusetts , November 24, 2015 ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ... Poulton , Chief Financial Officer, will participate in the Piper Jaffray ... City , NY on Tuesday, December 1, 2015, at 8:30 ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):